For instance, the Food and Drug Administration (FDA)-approved Prosigna breast cancer gene signature assay, based on the PAM50 intrinsic subtype classification model [39], provides assessment of 10-year risk of distant recurrence of post-menopausal ER+ patients. Here, ESR1 is linked to breast carcinoma.